Reduced dosing of the HPV vaccine for women living with HIV
Official title: A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV
Run by University of British Columbia · NCT05495906 · Data updated 2026-11-12
This study is testing if a lower dose of the HPV vaccine can effectively protect women living with HIV from HPV and cervical cancer.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 275 (estimated) |
| Sponsor | University of British Columbia Academic / other |
| Locations | 10 sites (Surrey, British Columbia and 9 other locations) |
| Status | Recruiting |
| Started | July 27, 2023 |
| Main results expected | August 2026 |
| Study ends | January 2028 |
| Registry record updated | February 5, 2026 |
| Trial ID | NCT05495906 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women aged 18-45 living with HIV who have not received any HPV vaccine.
✕Probably not a fit
Patients who are pregnant, have previously received an HPV vaccine, or have allergies to the vaccine components may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effectiveness of a reduced-dose schedule of the nonavalent HPV vaccine in women living with HIV, a group that is particularly vulnerable to HPV and cervical cancer. The study aims to enroll women aged 18-45 who have not previously received an HPV vaccine, with the goal of evaluating the feasibility of vaccination programs in this population. By focusing on reduced dosing, the trial seeks to contribute to global efforts to eliminate cervical cancer as outlined by the World Health Organization. Participants will be randomly assigned to receive the vaccine and monitored for outcomes related to HPV prevention.
Why it matters
Potential benefit: If successful, this study could significantly improve HPV vaccination rates and cervical cancer prevention among women living with HIV.
How similar studies have gone: While there is limited data on reduced-dose HPV vaccination in women living with HIV, similar studies have shown promise in other populations, making this approach both novel and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Living with HIV * Has a uterine cervix Exclusion Criteria: * Unable to give fully informed consent * Pregnant or unwilling to avoid pregnancy during vaccination * Allergy to the vaccine or its components * Prior receipt of any HPV vaccine
Where it's running
-
University of British Columbia
Vancouver, British Columbia, Canada Recruiting -
St. Michael's Hospital
Toronto, Ontario, Canada Recruiting -
Toronto General Hospital
Toronto, Ontario, Canada Recruiting -
Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, Canada Recruiting -
Centre Hospitalier de l'Université Laval
Québec, Quebec, Canada Recruiting -
Positive Health Services - Fraser Health
Surrey, British Columbia, Canada Not yet recruiting
Show 4 more locations
-
Health Sciences Centre
Winnipeg, Manitoba, Canada Not yet recruiting -
Hamilton Health Sciences
Hamilton, Ontario, Canada Not yet recruiting -
McGill University Health Centre
Montreal, Quebec, Canada Not yet recruiting -
Regina General Hospital
Regina, Saskatchewan, Canada Not yet recruiting
Study contacts
- Study coordinator: Deborah Money, MD
- Email: deborah.money@ubc.ca
- Phone: 6048752194
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CHW4CervixHealth: HPV self-collection kits with community health workers
This project will test whether giving self-collection HPV kits during community workshops led by community health workers helps increase screening among under-screened women aged 25–65 and will first compare kit results to clinical Pap smears.
-
Lower radiation therapy combined with standard chemotherapy for HPV-positive throat cancer
This study is testing whether using less radiation therapy along with standard chemotherapy can help people with HPV-positive throat cancer feel better while causing fewer side effects.
-
Can people collect their own vaginal sample for HPV testing as well as clinician collection for comparison?
This study tests whether individuals can correctly use a self-collection device to gather a vaginal sample for high-risk HPV screening and whether the self-collected sample agrees with clinician-collected samples.
-
HPV self-sampling in the ED to screen under-screened women
This study tests whether giving an HPV self-sampling kit in the emergency department can help under-screened women get screened for cervical cancer and find those with HPV to guide follow-up care.
-
Two-probe thermal ablation for cervical precancer in WLWH in South Africa
This study tests whether using two probes for thermal ablation is safer or more effective than one probe for treating cervical precancer in women living with HIV in South Africa.
-
Two-probe thermal ablation for cervical precancer in WLWH in Zimbabwe
This study tests whether using two TA probes (endocervical and ectocervical) is better than one probe for treating cervical precancer in women living with HIV in Zimbabwe.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.